

Index

Note: Page numbers referencing figures are followed by an “f”; page numbers referencing tables are followed by a “t”.

A

Abbe, Ernst, 370
absorbing probes, 249–253
acanthocytes, 339, 340f
actin, 346, 393f
activatable molecular probes, 248
acute leukemia, 338
acute lymphoblastic leukemia (ALL), 219
adducin, 346, 359
adenocarcinoma, 69f
adenosine triphosphate (ATP), 356–360
 measurements of, 356–357
 metabolism, 360
adipocytes, 12, 162f
advanced plasmonic materials, 306–310
AFB stain, 72
AFM. *See* atomic force microscopy
age-related macular degeneration (ARMD), 130–131, 135
Airy, G.B., 370–371
albedo, 83
ALL. *See* acute lymphoblastic leukemia
amblyopia, 137
Amdahl’s law, 294
Amoeba proteus, 158
Ampère’s circuital law, 15
amyloid beta plaques, 218
amyloid deposits, 72
anaphase, 5
anaplasia, 11
anchorage dependence, 7
angiogenesis, 10, 207
angular scattering, 350
angular spectra, 19
anisocytosis, 341f
anisotropic, 16, 84
anisotropy factor, 93
anomalous dispersion, 32
anti-Stokes signal, 161
APD. *See* avalanche photo diode
aphakia, 131
Apium graveolens, 250
apoptosis, 320

arbitrary geometric systems, 49
arbitrary particles, 82f
Argus I, 136
Argus II, 136
ARMD. *See* age-related macular degeneration
artificial vision, 135–137
A-scan, 144
astigmatism, 127
astrocytoma, 217
ATP. *See* adenosine triphosphate
ATR. *See* Attenuated Total Reflection
Attenuated Total Reflection (ATR), 210
ATTO-TEC (per company website), 382
autocorrelation function, 95
avalanche photo diode (APD), 44
Avastin, 130–131
Axelrod, D., 371
axial direction, 390–392
axial resolution, 147–148

B

backscattering cross section, 83
backward second-harmonic generation, 109–110, 281–282
Baddeley, D., 378
bar code-driven systems, 70
Barrett’s esophagus, 216
basophilic stippling, 341f
Bates, M., 382, 389
BBO. *See* beta barium borate
beam splitter, 43–44
Beer’s law, 46
bending failure, 125, 133–134
bending modulus, 355f
benign prostatic hypertrophy (BPH), 215
benign tumors, 8
beta barium borate (BBO), 105
beta blockers, 130
Betzig, E., 370n, 373, 380
Bewersdorf, J., 372, 385
bilateral vision loss, 128f
Billouin zone point, 313
biological window, 236
biplane FPALM, 393f

- bite cells, 340*t*
 Biteen, J.S., 382
 blindness, 124–126
 bending failure resulting in, 125
 causes of, 119–120
 conduction failure resulting in, 126
 definitions of, 118
 detection failure resulting in, 125–126
 focusing failure resulting in, 125
 legal, 118
 processing failure resulting in, 126
 transparency failure resulting in, 124–125
 Bloch formalism, 315
 Bloch wave, 183
 blood film, 338
 Blue-Gene/L cluster, 294, 308
 Boltzmann constant, 90
 Born approximation, 84
 Bossi, M., 388
 boundary conditions
 low-reflecting, 50
 matched, 50
 Maxwell's equations, 16–17
 TE, 49
 TM, 49
 bounded optical wavefunction, 39*f*
 bovine serum albumen (BSA), 242
 Bowen's disease, 218
 BPH. *See* benign prostatic hypertrophy
 brain cancer, 217–218
 BRCA1, 13
 BRCA2, 13
 breast cancer, 9*f*, 13, 202, 214
 Bretschneider, S., 373
 Brewster angle, 27–28
 Brownian dynamics, 356–357
 Brownian particles, 89
 BSA. *See* bovine serum albumen
 bulk plasmon, 179*f*
 Burr cells, 340*t*
- C**
- C6 matrix, 275
 CALU-1, 213
 Campagnola group, 273
 cancer cell
 biology of, 3–13
 division in, 8*f*
 molecular biology of, 12–13
 cancer pathology, 202–203. *See also specific cancers*
 cannula, 132
 capsulotomy, 122
 carcinoma, 69*f*
 cardiovascular disease, 219–220
 Carl Zeiss Axiovert 200, 332
 carriers, 21
 CARS. *See* Coherent Anti-Stokes Raman Scattering
 Cartesian coordinates, 52
 cataract, 119*f*
 CBC. *See* complete blood count
 CD117, 75
 CdSe quantum dots, 41*f*
 cell cycle, 4–7
 cell deformability assay, 343
 cell division, 4
 in cancer cells, 8*f*
 in normal cells, 8*f*
 Cell Theory, 3–4
 centrosymmetric molecules, 107*f*
 cervical cancer, 216–217
 cervical intraepithelial neoplasia (CIN), 217
 checkpoints, 6–7
 Cheezum, M.K., 380
 chemical imaging, 205
 chlorpromazine, 341
 Choudhur, A., 372
 chromatin, 4, 6
 chronic lymphocytic leukemia, 338
 Chudakov, D.M., 381–382
 CIN. *See* cervical intraepithelial neoplasia
 CLIA Act. *See* Clinical Laboratory Improvement Amendments
 Clinical Laboratory Improvement Amendments (CLIA) Act, 70
 CODE V, 117
 codocytes, 340*t*
 coherence function, 147
 coherence imaging probes, 242–260
 absorbing, 249–253
 dynamic, 244–249
 scattering, 242–244
 Coherent Anti-Stokes Raman Scattering (CARS), 142, 161
 collagen, 106
 collagen-based systems, 271–285
 College of American Pathology, 62
 colloidal nanoparticles, 298
 colorectal cancer, 215–216
 common natural materials, 174*t*
 complete blood count (CBC), 337
 complex geometric domains, 49
 computational nano-optics, 291–296
 computed tomography (CT), 236
 conduction failure, 126
 conductivity, 16
 confocal microscope
 OTF for, 384*f*
 PSF for, 384*f*
 congo red stain, 72
 connective tissue, 162*f*
 constitutive relations, 16
 contrast agents, 237–242
 convolution perfectly matched layers (CPML), 292, 294
 CoolSNAP, 332
 cornea, 121
 macroscopic features of, 121
 microscopic features of, 121
 couching, 131
 Coulomb potential, 38
 CPML. *See* convolution perfectly matched layers
 Cremer, C., 372
 critical angle, 26
 cryptosporidium parvum, 72
 CT. *See* computed tomography
 CTAB. *See* hexadecyltrimethylammonium bromide
 Cy5.5, 248, 249
 cyclospora, 72

Cysteamine, 323, 325*f*, 332
 cytochrome c, 320, 321, 325, 327*f*, 329*f*
 conjugated gold nanoparticles, 332
 oxidized, 323
 preparation of, 332
 cytokinesis, 6
 cytology specimen, 71–72
 cytoskeleton, 344*f*

D

dacryocytes, 340*t*
 dark-field condenser lens, 329, 330
 dark-field microscopy, 359
 data cube, 206
 Davidson, M.W., 382
 Day, R.N., 382
 de Mery, Jean, 129
 delta-function peak, 181
 Dendra2, 381
 density-dependent inhibition, 7
 deoxy-hemoglobin, 328*f*
 detection failure, 125–126
 detector integrity, 135–137
 dextran, 240, 245
 D-glucose, 357
 Di Francia, G., 372
 diabetes mellitus, 219
 diagnostic tools, 126–129
 DIC. *See* differential interference microscopy
 dichroic beam splitter, 111, 375*f*
 Dickson, R.M., 382
 dielectric function satisfying Kramers–
 Kronig relation, 185*f*
 dielectric particles
 elastic light scattering of, 81–83
 volume distribution of, 86–87
 dielectric permeability, 31*f*
 dielectric permittivity, 16
 dielectric plates, 186*f*
 dielectric polystyrene nanoparticles, 324
 dielectric susceptibility, 30
 differential interference microscopy (DIC),
 346, 347
 diffraction limit, 191–194
 diffraction-phase microscopy (DPM), 350,
 354–356, 362*f*
 diffraction-unlimited resolution, 372
 diffusion approximation, 93–94
 diffusion equation, 94
 diffusive wave spectroscopy (DWS), 94–96
 digital holography, 350
 dipolar resonance, 181
 directionality, 108
 discocyte, 352*f*, 355*f*
 discrete mesh grid, 52
 discrete reflector models, 145*f*
 dispersion relation, 18, 19
 DIV. *See* days *in vitro*
 DNA, 4
 DNG. *See* double negative
 Donnert, G., 377, 389
 Doppler OCT, 141
 double negative (DNG), 174, 189–190
 double positive (DPS), 174
 double-ended excitation, 312
 DPM. *See* diffraction-phase microscopy

DPS. *See* double positive
 drepanocytes, 339, 341*t*
 DRIMAPS, 349
 Dronpa, 382
 Drude model, 33–35, 178, 291, 292*f*
 Drude parameters, 291
 Drude–Lorentz model, 291, 292*f*
 DWS. *See* diffusive wave spectroscopy
 dynamic light scattering, 88, 89*f*
 dynamic probes, 244–249
 dysplasia, 10, 11*f*

E

echinocytes, 340*t*, 351, 352*f*, 355*f*
 EDC. *See* ethyl-3-[3-dimethylaminopropyl]
 carbodiimide hydrochloride
 EDTA. *See* ethylenediaminetetraacetic acid
 effective electric permittivity, 185–187
 effective magnetic permeability, 187–189
 effective medium, 182–184
 E-field, 384, 385
 EGFR. *See* Epidermal Growth Factor
 Receptor
 ektacytometry, 347
 elastic cartilage, 280
 elastic light scattering, 81–87
 of dielectric particles, 81–83
 Mie theory and, 85–86
 electric field, 15, 51*f*, 53*f*
 electric induction, 16
 electric permittivity, 175*f*, 185–187
 electromagnetic fields, 15–35, 287–288
 electromagnetic picture, 100–107
 electron wave, 38
 electron wavefunction, 38–39, 39*f*
 electron-multiplying charge-coupled device
 (EMCCD), 379
 elementary volume, 92*f*
 ellipsoids, 290*f*
 elliptocytes, 339*f*, 340*t*
 elliptocytosis, 338
 EM energy coupling, 333
 EM energy distribution, 333
 EM energy propagation, 297
 EM field distribution, 307
 EM near-field dynamics, 287–288
 embryonic chick cardiomyocyte, 157
 EMCCD. *See* electron-multiplying charge-
 coupled device
 energy propagation, 176*f*
 energy velocity, 21–23, 176
 ENG. *See* epsilon-negative
 enhanced permeability-and-retention (EPR),
 241
 envelope, 21
 EosFP, 381, 388
 eosin, 62, 68, 76*f*, 338
 Epidermal Growth Factor Receptor (EGFR),
 75, 253–254, 255
 epiretinal prosthesis, 135–137
 epithelial tissues, 12
 EPR. *See* enhanced permeability-
 and-retention
 epsilon-negative (ENG), 174, 191–192
 erythrocyte nanoscale flickering, 337–362
 estrogen receptors, 75

ethyl-3-[3-dimethylaminopropyl]
 carbodiimide hydrochloride (EDC), 332
 ethylenediaminetetraacetic acid (EDTA), 350
 evanescence, 27
 evanescent fields, 27*f*
 excimer laser, 135
 eye
 anatomy of, 120
 macroscopic, 120
 microscopic, 120–121

F

facing, 66
 factor VIII, 207
 fallopian tube, 61*f*
 Faraday's induction law, 15
 FD-OCT. *See* Fourier-domain OCT
 FDTD. *See* finite difference time domain
 FEM. *See* finite element method
 FEMLAB, 333
 fibrillar collagen, 272
 fibroblasts, 12
 Fick's law, 94
 field distribution, 180*f*
 field reflective coefficient, 25
 field testing, 127
 field vectors, 176*f*
 fine-needle aspiration, 57
 finite difference time domain (FDTD),
 52–53, 191, 291, 292, 293, 294
 accuracy of, 295
 GA and, 308
 independent runs, 303
 schematical setup of, 302*f*
 silver nanocavity produced from, 53*f*
 simulations, 295*f*, 304, 306
 finite element method (FEM), 49, 50*f*
 finite element simulation, 333
 fishnet structure
 metal-dielectric-metal, 190*f*
 metamaterials, 190
 fixed-frequency contours, 193*f*
 flag, 338
 FLIC. *See* fluorescence interference contrast
 floaters, 68
 fluorescence imaging, 237
 fluorescence interference contrast (FLIC), 348
 fluorescence photoactivation localization
 microscopy (FPALM), 373, 378, 379*f*,
 386, 392, 394, 396
 application example of, 393*f*
 biplane, 393*f*
 OTF and, 387–388
 fluorescent probes (FPs)
 photoactivatable, 381
 in superresolution microscopy, 380–382
 Fluorescent Resonance Energy Transfer
 (FRET), 320
 fluorophore, 99
 flux density, 16
 focusing, 110, 119
 failure, 125
 restoring, 133–134
 Folling, J., 378, 382
 forbidden zones, 38

Fort Orange quantum dots, 252
 forward second-harmonic generation, 281–282
 forward-to-backward second harmonic
 generation, 273
 4Pi microscopy, 373
 Fourier peaks, 284*f*
 Fourier phase microscopy, 156
 Fourier theory, 383
 Fourier transform, 29, 84
 Fourier transform infrared (FT-IR), 205–206,
 208, 218
 applications, 211–220
 brain cancer and, 217–218
 breast cancer and, 214
 cardiovascular disease and, 219–220
 cervical cancer and, 216–217
 clinical applications of, 214–220
 clinical considerations, 220
 colorectal cancer and, 215–216
 gastric cancer and, 216
 molecular pathology and, 206–208
 other cancers and, 218–219
 prostate cancer and, 214–215
 routine use, 220–222
 skin cancer and, 218
 spectroscopic considerations, 220–221
 translation of, to clinic, 221
 2D cell culture, 211–212
 Fourier Transform Light Scattering (FTLS),
 350
 Fourier transform operator, 17
 Fourier-domain images, 247
 Fourier-domain OCT (FD-OCT), 141, 143, 149
 Fourier-phase microscopy (FPM), 350
 Fourier-transform second-harmonic
 generation, 277–281
 magnitude spectrum peaks, 280–281
 maximum spatial frequency, 279–280
 preferred orientation, 277–279
 FPALM. *See* fluorescence photoactivation
 localization microscopy
 FPM. *See* Fourier-phase microscopy
 FPs. *See* fluorescent probes
 Fraunhofer diffraction, 384
 free-space photon, 179
 French Royal Academy, 129
 frequency space, 387*f*
 frequency-domain solution, 29
 Fresnel coefficients, 311
 Fresnel conditions, 310
 Fresnel equations, 23–26, 33
 FRET. *See* Fluorescent Resonance Energy
 Transfer
 frozen block, 63*f*
 frozen sections, 62–64
 FT-IR. *See* Fourier transform infrared
 FTLS. *See* Fourier Transform Light
 Scattering
 Fugene 6, 326
 full-field measurements, 348
 FWHM wavelength, 148

G

G₁ phase, 7
 G₂ phase, 4, 5*f*

G_2 phase, 4, 5*f*
 GA. *See* genetic algorithm
 gallbladder, 60*f*
 gastric biopsy, 73*f*
 gastric cancer, 216
 Gaussian beam, 110
 Gaussian mask algorithm, 380
 Gaussian statistics, 358
 genetic algorithm (GA), 306–310
 FDTD, 308
 standard procedure, 307–308
 Giardia, 72
 Giemsa stain, 72, 338
 glaucoma, 159
 Gleason grading system, 215
 Gleevac therapy, 75
 glioma, 12, 217
 glutaraldehyde, 352*f*, 353
 glycoporphins, 345
 GMS stain, 72
 GNRs. *See* gold nanorods
 gold nanocages, 257–259
 gold nanoparticles, 319–323, 331
 cytochrome c conjugated, 332
 raw scattering spectra of, 327*f*
 scattering imaging of, 332–333
 spectroscopy of, 332–333
 gold nanorods (GNRs), 256–257
 gold nanoshells, 150
 Golgi apparatus, 396
 gonioscopy, 128
 Goodman, J.W., 383
 Gordon, M.P., 377, 390
 Gould, T.J., 374, 380, 389, 397
 Gouy phase shift, 110
 ground-state depletion, 373
 group velocity, 21–23
 growth medium, 7
 Gustafsson, M.G., 372, 385
 gyromagnetic imaging, 247

H

HA. *See* Hypocrellin A
 Harke, B., 391
 harmonophores, 276
 HAuCl_4 , 240–241, 259
 HCA. *See* Hierarchical Cluster Analysis
 H&E. *See* hematoxylin and eosin
 Hecht, E., 384
 Heilemann, M., 382
 Hein, B., 382
 Heintzmann, R., 372
 Heinz bodies, 341*t*
 HeLa, 7–8, 212
 Helicobacter pylori, 72, 73*f*
 Hell, S.W., 372, 373, 394
 Helmholtz equation, 18–19
 hematoxylin, 62, 68, 76*f*
 hematoxylin and eosin (H&E), 204, 207*f*,
 213*f*
 Heme group, 324
 hemoglobin, 250, 328*f*
 hemoglobin C disease, 338
 HER-2. *See* human epidermal growth factor
 receptor 2
 Herceptin therapy, 75
 hereditary spherocytosis, 338
 Hertz potentials, 85
 Hess, S.T., 373, 378
 hexadecyltrimethylammonium bromide
 (CTAB), 240
 Hierarchical Cluster Analysis (HCA), 218
 Hilbert phase microscopy, 156
 Hilbert-phase microscopy (HPM), 350
 Hochstrasser, R.M., 378
 Holtzer, L., 392
 Hooke, Robert, 3, 370
 Hooke's law, 98
 hooklets of cysticerci, 72
 Horn microscopy, 349
 Howell Jolly bodies, 341*t*
 HPM. *See* Hilbert-phase microscopy
 HRS. *See* hyper-Rayleigh scattered
 Huang, B., 392
 human epidermal growth factor receptor 2
 (HER-2), 74, 150, 254
 Humayun, Marc, 136
 hyaline cartilage, 280
 hyperlens, 192–193
 hyperopia, 125
 hyperplasia, 10
 hyper-Raman scattering, 194
 hyper-Rayleigh scattered (HRS), 108
 Hypocrellin A (HA), 212

ISAM. *See* interferometric synthetic aperture microscopy
 Isospora, 72
 isotropic scattering, 46

J

Jablonski diagram, 98, 99f
 Jacobson, K., 373
 Jones matrix, 159
 Juette, M.F., 392

K

kDa-range, 381
 KDP. *See* potassium dihydrogen phosphate
 keratocytes, 340f
 keratome, 135
 Klar, T.A., 374, 391
 Kner, P., 372
 Kramers–Kronig relation, 184, 185f
 Kroug, M., 373
 Kupffer cells, 244f

L

Lacoste, T.D., 377
 Lagerholm, B.C., 377
 Lambert–Beer law of attenuation, 87
 LASIK, 121, 122, 134–135
 lateral junctional complexes, 345f, 346
 lateral resolution, 147–148
 layer-by-layer (LBL) adhesion, 242
 LBL adhesion. *See* layer-by-layer adhesion
 LCI. *See* low-coherence interferometry
 LCPM. *See* liquid crystal phase modulator
 lead poisoning, 338
 Leeuwenhoek, Anthony van, 3
 legal blindness, 118
 legal drive, 118
 Legendre expansion, 93
 Lemmer, P., 382
 lens, 122–123
 dark-field condenser, 329, 330
 hyper, 192–193
 imperfect, 177
 intraocular, 133f
 macroscopic features of, 122
 microscopic features of, 122–123
 objective, 375f
 perfect, 177, 191
 solid immersion, 210
 super, 177, 178f, 191–192
 transparency of, 124–125
 lensmaker's equation, 134
 leukemia, 12
 acute, 338
 acute lymphoblastic, 219
 chronic lymphocytic, 338
 Lidke, K.A., 377
 light scattering, 81–96
 by arbitrary particles, 82f
 dynamic, 88
 elastic, 81–87
 multiple, 90–96
 properties, 81–83

light scattering (*Cont.*):
 quasi-elastic, 88–90
 total cross section of, 82
 light wave, 38
 light-matter interaction, 28
 light-metals interaction, 33–35
 LiNbO₃. *See* lithium niobate
 linear optics, 97
 linear susceptibility, 100
 lipo-transfection, 326
 Lippincott-Schwartz, J., 381
 lithium niobate (LiNbO₃), 105
 live-cell imaging, 389–390
 localization-based microscopy, 377–380
 localized surface plasmon, 180
 localized surface plasmon-polariton resonance (LSPPR), 288–289, 300
 shape sensitivity of, 289f
 waves, 309
 localized surface plasmons (LSP), 253
 long-range plasmon, 310
 Lorentz model, 28, 29–33
 macroscopic response in, 29–31
 microscopic response in, 29–31
 response above resonance, 32, 33
 response below resonance, 32
 Lorentz oscillator model, 98
 Lorentzian function, 184, 187
 Lorentzian line, 32
 low-coherence interferometry (LCI), 140
 basic theoretical aspects of, 143–149
 molecular-specific, 160–162
 in nanomedicine, 149–161
 phase-sensitive, 156–159
 theoretical aspects of, 143–149
 low-reflecting boundary conditions, 50
 L-particle, 303–304
 LPM. *See* Laplacian Phase Microscopy
 LSP. *See* localized surface plasmons
 LSPPR. *See* localized surface plasmon-polariton resonance
 LUCENTIS, 130–131
 luciferase, 237
 lymphoma, 12
 lysosomal proteases, 248

M

Machemer, Robert, 132
 macrocytes, 339, 341f
 macrocytosis, 340f
 macrometastases, 10
 macroscopic response, 29–31
 magnetic charge, nonexistence of, 16
 magnetic field intensity, 16
 magnetic flux density, 15
 magnetic induction, 15
 magnetic nanoparticles (MNPs), 152
 magnetic permeability, 16, 175f
 magnetic resonance imaging (MRI), 142, 236
 magnetite, 239
 magnetomotive OCT, 141, 142, 152–154, 240, 243, 246–247
 magnitude spectrum, 280–281
 magnitude spectrum peaks, 284–285
 malaria, 338, 360

- malignant tumors, 9
 Manley, S., 390
 matched boundary conditions, 50
 MATLAB, 333
 matrix metalloproteinases (MMPs), 248
 maximum spatial frequency, 279–280
 Maxwell curl equations, 52
 Maxwell equations, 315
 Maxwell–Bloch equations, 315
 Maxwell’s equations, 15–28, 35, 99
 boundary conditions, 16–17
 NSOM and, 46–48
 in representations, 19–21
 in space-frequency representation, 17–18
 in space-time representation, 15–16
 MCHC. *See* mean cell hemoglobin concentration
 mCherry, 381
 MCV. *See* mean corpuscular value
 MDR cell types. *See* multidrug-resistant cell types
 mean cell hemoglobin concentration (MCHC), 337
 mean corpuscular value (MCV), 337
 medical therapeutic tools, 130–131
 megaloblastic anemia, 340f
 melanin, 250
 melanoma, 218
 membrane displacements, 351–353
 dynamic behavior of, 353–356
 Message-Passing-Interface (MPI), 293
 metal clusters, 187
 metal cylinders, 187f
 metal nanoparticles
 inversion symmetry and, 302–306
 optics of, 302–306
 metal plates, 186f
 metal-dielectric-metal fishnet structure, 190f
 metallo-dielectric nanoparticles, 288
 metamaterials, 173–195
 common natural materials *vs.*, 174f
 composition of, 173
 design of, 182–190
 DNG, 189–190
 effective electric permittivity, 185–187
 effective magnetic permeability, 187–189
 effective medium, 182–184
 fishnet structure, 190
 unit cell of, 189f
 metaphase, 5
 metaphase plate, 6
 metaplasia, 10, 11f
 metastasis, 9
 methoxypropylglycol succinate (MPEG), 248
 methylene blue, 338
 Meyer, L., 389
 microcytic RBCs, 339
Micrographia (Hooke), 370
 micrometastases, 10
 microphotonic devices, 40f
 microscopic response, 29–31
 microspherocytes, 340f
 microtomes, 63f, 64
 problems associated with, 68
 sectioning of paraffin blocks, 66–68
 microtubules, 6, 272
 microtubulin, 106
 mid-infrared (MIR), 205
 Mie coefficients, 85
 Mie formalism, 86
 Mie scattering, 331
 Mie scattering theory, 45–46
 Mie theory, 85–86, 150, 253
 Mileusis, 135
 MIR. *See* mid-infrared
 mitosis, 4
 mitotic phase, 4
 Mlodzianoski, M.J., 392
 MMF. *See* multimode fiber
 M-mode imaging, 246
 MMPs. *See* matrix metalloproteinases
 MNG. *See* mu-negative
 MNPs. *See* magnetic nanoparticles
 molecular contrast agents, 237–242
 molecular fingerprints, 206
 molecular imaging techniques, 236–237
 molecular pathology, 205–206
 momentum transfer, 89
 monochromatic light beam, 330
 monolayer slide, 71
 monostatic radar configuration, 87
 MPEG. *See* methoxypropylglycol succinate
 MPI. *See* Message-Passing-Interface
 MPM. *See* multiphoton microscopy
 MQM. *See* multiple quantum wells
 MRI. *See* magnetic resonance imaging
 multicolor imaging, 388–389
 multidrug-resistant (MDR) cell types, 212
 multimode fiber (MMF), 375f
 multiphoton fluorescence, 194
 multiphoton microscopy (MPM), 236
 multiple myeloma, 338
 multiple quantum wells (MQM), 39
 multiple scattering, 90–96
 mu-negative (MNG), 174
 Murphy’s law, 119
 mutually orthogonal vectors, 20f
 myopia, 125
 myosin, 106, 272, 276, 359
- N**
- NA. *See* numerical aperture
 NaCl, 273
 nanocages, 238, 240
 gold, 257–259
 nanorescent device, 51f
 nanomedicine, 140
 LCI-based techniques for, 149–161
 OCT applications in, 141–143
 nanometer accuracy, 75
 nano-optics, 306–310
 nanoparticles (NPs), 238
 colloidal, 298
 dielectric polystyrene, 324
 gold, 319–323, 331–333
 iron-oxide, 239, 243, 245, 247
 magnetic, 152
 metal, 302–306

nanoparticles (NPs) (*Cont.*):
 metallo-dielectric, 288
 1D arrays of, 299–302
 optics of, 302–306
 silver, 319–320
 super-paramagnetic iron-oxide magnetic nanoparticles, 238, 255
 nanophotonics, 37–53
 computation in, 44–53
 foundations, 38–39
 plasmonics and, 41–43
 simulation in, 44–53
 nanoplasmonic particles, 326–327
 nanoprobes
 absorbing, 235–261
 modulating, 235–261
 scattering, 235–261
 nanorods, 238, 240
 gold, 256
 nanoscale architecture, 75
 nanoshell-enhanced OCT, 254
 nanoshells, 238, 240
 gold, 150
 nanospheres, 238
 nanostars, 238, 240
 nanostructures, 238
 nanotubes, 238
 single-walled carbon, 260
 nanowires, 238
 nasopharyngeal carcinoma, 254
 National Academy of Science, 37
 near-field scanning optical microscopy (NSOM), 43–44
 aperture-mode, 44f
 configurations of, 43f
 Maxwell's equations and, 46–48
 Mie scattering theory, 45–46
 negative index materials, 175f
 negative refraction, 176, 177f
 neoplasia, 10, 11f
 Neumann function, 46
 neuroblastomas, 12
 NHLF. *See* normal human lung fibroblast
 NIR radiation, 150
 NIRF, 237, 243, 248
 NIVI. *See* nonlinear interferometric vibrational imaging
 noise, 148–149
 Nomarski microscope, 158f
 non-centrosymmetry, 105–107
 nonexistence of magnetic charge, 16
 non-Gaussian parameters, 358
 nonlinear interferometric vibrational imaging (NIVI), 160–162
 nonlinear media, 16
 nonlinear microscopy, 98–99
 nonlinear wave equation, 101–102
 nonperfect phase matching, 105–106
 normal dispersion, 32
 normal human lung fibroblast (NHLF), 254
 normalized Gaussian function, 147
 NPs. *See* nanoparticles
 NSOM. *See* near-field scanning optical microscopy
 numerical aperture (NA), 371
 Nyquist frequency, 380

O

OBJ. *See* objective lens
 objective lens (OBJ), 375f
 OCM. *See* optical coherence microscopy
 OCT. *See* optical coherence tomography
 OLCR. *See* optical low-coherence reflectometry
 oncogenes, 12
 IPE. *See* one-photon excitation
 one-photon excitation (IPE), 386
 optic nerve, 119, 124
 macroscopic features of, 124
 microscopic features of, 124
 restoring conduction in, 137
 Optica, 117
 optical coherence microscopy (OCM), 154
 optical coherence tomography (OCT), 94, 129, 140, 236
 applications in medicine, 141
 applications in nanomedicine, 141–143
 axial resolution, 147–148
 Doppler, 141
 Fourier domain, 141, 149
 functional extensions of, 149–161
 image reconstruction, 144f
 lateral resolution, 147–148
 magnetomotive, 141, 142, 152–154, 240, 243, 246–247
 nanoshell-enhanced, 254
 noise in, 148–149
 origin of, 140–141
 photothermal, 240
 polarization-sensitive, 141, 142, 159–160
 pump-probe, 160–162, 252
 second-harmonic, 141
 sensitivity in, 148–149
 SNR in, 148–149
 spectral domain, 146–147
 spectroscopic, 141, 142, 151–152, 249, 251–252, 257, 258
 swept-source, 149
 theory, 144–146
 time domain, 141, 148
 ultrahigh-resolution, 154–156
 optical Doppler tomography, 237
 optical field enhancement, 42–43
 optical low-coherence interferometric techniques, 139–163
 optical low-coherence reflectometry (OLCR), 140
 optical sectioning, 371
 optical spectrum, 22
 optical therapeutic tools, 129–130
 optical transfer function (OTF), 382–388
 for confocal microscope, 384f
 FPALM and, 387–388
 image formation, 382–386
 STED and, 386–387
 oscillator strength, 30
 Osler, William, 115
 osmolarity, 361f
 osmotic pressure, 360
 osteoblasts, 12
 OTF. *See* optical transfer function
 Otto geometry, 310
 oxy-hemoglobin, 328f

P

- P. falciparum*, 360–362
 PAFPs. *See* photoactivatable FPs
 PALM. *See* photoactivated localization microscopy
 PAm-Cherry, 381, 389
 pap smear, 71
 paraffin, 64
 melted, 65
 sectioning of, 66–68
 tissue blocks after, 65*f*
 Parel, Jean Marie, 132
 parenchyma, 162*f*
 Parkinson's disease, 218
 partial differential equations (PDEs), 49
 particles, 81. *See also* nanoparticles
 arbitrary, 82*f*
 Brownian, 89
 dielectric, 81–83
 L, 303–304
 light scattering by arbitrary, 82*f*
 Rayleigh, 83–84
 spherical, 85*f*
 volume distribution of, 86–87
 PAS stain, 72
 PAT. *See* photo-acoustic tomography
 pathology report, 74
 Patterson, G.H., 381
 Pavani, S.R., 392
 Pawley, J.B., 371
 PC. *See* phase contrast
 PCM. *See* phase-contrast microscopy
 PDEs. *See* partial differential equations
 PE. *See* phosphatidyl ethanolamine
 PEGs. *See* polyethylene glycols
 penetration depth, 112
 perfect coupling, 310–314
 perfect lens, 177, 191
 perfectly matched layers (PML), 292
 peripheral blood smear, 340*t*
 peripheral proteins, 345–346
 PET. *See* positron emission tomography
 phacoemulsification, 131
 phase function, 83
 phase mismatch factor, 103, 104*f*
 phase plate (PP), 375*f*
 phase velocity, 21–23, 176
 phase-contrast microscopy (PCM), 346–347
 phase-matching bandwidth, 106–107
 phase-polarization control scheme, 296–298
 phase-sensitive LCI, 156–159
 phoropter, 127*f*
 phosphatidyl choline, 344
 phosphatidyl ethanolamine (PE), 344
 phosphatidyl serine (PS), 344
 phospholipids, 344
 photo-acoustic tomography (PAT), 240
 photoactivatable FPs (PAFPs), 381
 photoactivated localization microscopy (PALM), 373, 392
 photobleaching, 327*f*
 photomultipliers, 111
 photon-plasmon interaction, 35
 photorefractive keratectomy (PRK), 134–135
 photothermal microspectroscopy (PTMS), 210
 photothermal OCT, 240
 phototoxicity, 98
 pinhole imaging, 117
 plane wave solution, 19
 plasma frequency, 30
 plasmon oscillations, 288
 plasmon resonance, 41*f*
 plasmon resonance energy transfer (PRET), 319–334
 biomolecular absorption spectroscopy, 320–332
 critical energy matching for, 325*f*
 efficiency, 324
 EM energy coupling, 333
 experimental procedures, 332–333
 of nanoplasmonic particles in living cells, 326–327
 schematic diagram of, 321*f*
 whole-field intracellular, 327
 plasmon-driven light trapping, 299–302
 plasmon-quenching peak amplitude, 324
 plasmon-resonant gold nanoprobles, 150
 plasmonic diffraction gratings, 310–314
 plasmonics, 41–43, 287–317
 metamaterials and, 173–195
 optical field enhancement, 42–43
 plasmons
 bulk, 179*f*
 localized surface, 180
 surface, 178–182, 180*f*
 PML. *See* perfectly matched layers
 point-by-point transfer, 193*f*
 point-spread function (PSF), 370*f*, 371, 383, 384*f*
 for confocal microscope, 384*f*
 effective, 376*f*
 engineering, 374–377
 excitation, 376*f*
 polarization-sensitive OCT (PS-OCT), 141, 142, 159–160
 poling, 106
 polychromator entrance slit, 328
 polychromator spectrograph, 327
 polyethylene glycols (PEGs), 240
 polylysine, 248
 polyvinylpyrrolidone, 240
 positive refraction, 177*f*
 positron emission tomography (PET), 236
 potassium dihydrogen phosphate (KDP), 105
 potential well structures, 39*f*
 Poynting vector, 22, 82
 PP. *See* phase plate
 predictive markers, 74–75
 preferred orientation, 277–279, 282–285, 283*f*
 presbyopia, 122
 PRET. *See* plasmon resonance energy transfer
 PRK. *See* photorefractive keratectomy
 processing failure, 126
 prognostic markers, 74–75
 propagating wave vector, 47
 prophase, 5
 prostaglandin, 130
 prostate cancer, 202, 214–215
 prostate histology, 204*f*
 proto-oncogenes, 12
 Prussian blue stain, 72

PS. *See* phosphatidyl serine
 PSF. *See* point-spread function
 PS-OCT. *See* polarization-sensitive OCT
 PTMS. *See* photothermal microspectroscopy
 pump-probe OCT, 160–162, 252

Q

Q-factor, 289, 311
 QPI. *See* quantitative phase imaging
 Qu, X., 377, 390
 qualitative measurements, 348
 quantitative phase imaging (QPI), 348–351
 quantum dots, 39, 238
 CdSe, 41*f*
 fluorescence, 373
 Fort Orange, 252
 quantum optics, 116–117
 quantum wires, 39
 quantum-confined materials, 39–41
 quasi-elastic light scattering, 88–90
 quasi-phase matching, 106
 quasistatic limit, 186

R

radiative transport theory, 91–94
 Raman scattering, 101, 194
 Raman spectroscopy, 209
 Ramon y Cajal, Santiago, 129
 ray optics, 116–117
 Rayleigh criterion, 371
 Rayleigh limit, 379
 Rayleigh particles, 83–84
 Rayleigh regime, 84
 Rayleigh scattering, 98
 Rayleigh scattering spectrum, 321*f*, 323*f*
 Rayleigh–Debye scattering regime, 84
 RBCs. *See* red blood cells
 RCM. *See* reflectance confocal microscopy
 RDW. *See* red blood cell distribution width
 red blood cell distribution width (RDW), 337
 red blood cells (RBCs)
 deformability, 342*f*
 dynamics, 351–360
 full-field QPI, 349–350
 membrane fluctuations, 347–348
 membranes, 343–351
 microcytic, 339
 morphology, 339*f*
 morphology assay, 338–343
 osmotic pressure and, 360
 point measurements, 349
 shapes of, exposed to different osmolarity, 361*f*
 red reflex, 127
 red shift, 374
 reflectance confocal microscopy (RCM), 254
 reflection, 28
 reflection interference contrast microscopy (RICM), 348
 refractive errors, 117*f*
 refractive index, 19, 23*f*, 33, 184
 relative dielectric permittivity, 16

RES. *See* reticulo endothelial system
 RESOLFT. *See* reversible saturable optical fluorescence transitions
 restriction point, 5*f*, 7
 reticulin stain, 72
 reticulo endothelial system (RES), 241
 retina, 119, 123–124
 detachment, 135
 macroscopic features of, 123
 microscopic features of, 123–124
 retinitis pigmentosa (RP), 135
 reversible saturable optical fluorescence transitions (RESOLFT), 373, 374
 rheoscopy, 347
 Rhodamine-5G, 251
 Rhodamine-6G, 250
 rhodopsin, 123
 Riccati–Bessel functions, 45
 RICM. *See* reflection interference contrast microscopy
 Rittweger, E., 377
 RMS. *See* root-mean-squared
 Roche Diagnostics, 326
 root-mean-squared (RMS), 357
 RP. *See* retinitis pigmentosa
 Rust, M.J., 389

S

S phase, 4
 sarcomas, 12
 sarcomeres, 274*f*
 SAXS. *See* small-angle X-ray scatterings
 Saxton, M.J., 373
 scalar quantity, 91
 scanning electron microscopy (SEM), 4
 scattering efficiency, 85*f*
 scattering probes, 242–244
 schistocytes, 340*f*
 Schleiden, Mathias, 3
 Schmidt, R., 377
 Schonle, A., 394
 Schrödinger's electronic wave equation, 38
 Schwann, Theodor, 3
 SDPM, 157
 Second Sight, Inc., 136
 second-harmonic generation, 97–114
 advantages, 113
 backward, 109–110, 281–282
 of collagen-based systems, 271–285
 directionality, 108
 disadvantages, 113
 distinguishing, 112
 electromagnetics picture, 100–107
 experimental configuration, 110–112
 focusing and, 110
 forward, 281–282
 forward-to-backward, 273
 Fourier-transform, 277–281
 intensity, 102–105
 magnitude spectrum peaks, 284–285
 non-centrosymmetry, 105–106
 nonlinear microscopy, 98–99
 nonperfect phase matching, 105
 penetration depth, 112
 phase matching in biological tissues, 110

- second-harmonic generation (*Cont.*):
 phase mismatch factor *vs.*, 104*f*
 phase-matching bandwidth, 106–107
 power limitations, 112–113
 practical considerations, 112–113
 preferred orientation, 282–285
 quantitative information from, 273–281
 quasi-phase matching, 106
 resolution, 112
 schematic of, 272*f*
 theory of, 100–110
- second-harmonic OCT, 141
- second-order nonlinear polarization, 102
- second-order nonlinear susceptibility
 matrix, 275*f*
- second-order spherical Neumann function,
 46
- SEM. *See* scanning electron microscopy
- sensitivity, 148–149
- SERS. *See* surface-enhanced Raman
 spectroscopy
- Shaner, N.C., 381–382
- Shannon–Nyquist sampling frequency,
 390
- Shao, L., 385
- Sharonov, A., 378
- shear modulus, 355*f*
- Sheppard, C.J.R., 371, 372
- short-range mode, 310
- short-range SPP, 313
- short-time Fourier transform (STFT), 151
- sHPM. *See* stabilized Hilbert-phase
 microscopy
- Shroff, H., 388, 390
- Shtengel, G., 392
- Sickle cell, 339*f*
- Siegert-type relationships, 94
- signal velocity, 23
- SIL. *See* Solid Immersion Lens
- silver nanocavity, 53*f*
- silver nanoparticles, 319–320
- SIM. *See* structured illumination
 microscopy
- single photon emission computed
 tomography (SPECT), 236
- single-point measurements, 348
- single-scattering approximation, 86–87
- single-walled carbon nanotubes (SWNTs),
 260
- sinusoidal silver gratings, 290
- SKBR3, 259
- skin cancer, 218
- SLIM. *See* spatial light interference
 microscopy
- SLIT. *See* spatial light interference
 tomography
- SM. *See* sphingomyelin
- small-angle X-ray scatterings (SAXS), 214
- Snellen acuity, 118
- Snell's law, 25, 28
- SNR, 209
 in OCT systems, 148–149
- SNT. *See* semiconductor nanotubes
- Solid Immersion Lens (SIL), 210
- Soret band, 326
- space-frequency representation, 17–18
- spatial light interference microscopy (SLIM),
 75–76, 76*f*
- spatial wave vector, 346–347
- special stains, 72–74
- SPECT. *See* single photon emission
 computed tomography
- spectral dips, 320
- spectral-domain OCT, 146–147
- spectral-domain phase microscopy (SDPM),
 157
- spectrin, 345–346, 354, 359–360
- spectroscopic OCT, 141, 142, 151–152, 249,
 251–252, 257, 258
- spherical particles, 85*f*
- spherocytes, 339, 340*t*, 351, 352*f*, 355*f*
- sphingomyelin (SM), 344
- SPION. *See* super-paramagnetic iron-oxide
 magnetic nanoparticles
- SPP. *See* surface plasmon polariton
- spring constant, 34
- spur cells, 340*t*
- SRK formula, 134
- stabilized Hilbert-phase microscopy
 (sHPM), 353
- standard blood testing, 337–338
- STED. *See* stimulated emission depletion
- Steltzer, E.H.K., 372
- STFT. *See* short-time Fourier transform
- stimulated emission depletion (STED), 373,
 375*f*, 376*f*, 390
 application example of, 391*f*
 in OTF context, 386–387
 resolution in, 377
- STM. *See* scanning tunneling microscopy
- Stokes parameters, 310
- Stokes shift, 374
- Stokes vector analysis, 159
- Stokes–Einstein equation, 90
- Stokes–Einstein relationship, 95
- stomatocytes, 340*t*
- STORM, 382, 389, 392
- strabismus, 137
- stratum corneum, 218
- structured illumination microscopy (SIM),
 372
- Subach, F.V., 381
- subretinal prosthesis, 135–137
- superlens, 177, 178*f*, 191–192
- super-paramagnetic iron-oxide magnetic
 nanoparticles (SPION), 238, 255
- superresolution far-field fluorescence
 microscopy, 369–397
 applications, 388–392
 in axial direction, 390–392
 fluorescent probes in, 380–382
 fundamentals, 374–388
 for multicolor imaging, 388–389
 OTF and, 382–388
 recording time dependency, 395*t*
 resolution dependency, 395*t*
 temporal resolution, 389–390
- surface charge, 180*f*
- surface plasmon, 178–182
 field distribution, 180*f*
 localized, 180
 surface charge, 180*f*

surface plasmon polariton (SPP), 290
 resonance, 313
 short-range, 313
 surface plasmon resonant probes, 253–260
 surface plasmon wave, 48
 surface-enhanced Raman spectroscopy
 (SERS), 42–43, 181, 313–314, 319
 surgical therapeutic tools, 131–137
 swept-source OCT, 149
 Synchrotron Radiation Center, 209

T

Tamoxifen, 75
 tangential fields, 17
 TD-OCT. *See* time domain OCT
 TE. *See* transverse electric
 telophase, 5
 temporal resolution, 389–390
 tensor quantity, 30
 therapeutic tools, 129–137
 medical, 130–131
 optical, 129–130
 surgical, 131–137
 thin-film superlens, 191–192
 Thompson, R.E., 380
 3D tissue culture, 212–213
 thrombin clot, 71
 time domain OCT (TD-OCT), 141,
 143, 148
 time-frequency analysis, 151f
 time-harmonic form, 49
 TIRF. *See* total internal reflection
 fluorescence
 tissue block, 67f
 tissue pathology, 57–79
 tissue preparation, 58–60
 accessioning specimen, 58–60
 biopsy specimen, 59f
 frozen sections, 62
 grossing in specimen, 60–62
 mistakes in, 59
 tissue embedding, 64–66
 tissue processor, 64–66
 tissue staining, 68–71
 TM. *See* transverse magnetic
 total cross section of scattering, 82
 total internal reflection, 26–27
 total internal reflection fluorescence (TIRF),
 371
 TPL. *See* two-photon luminescence
 transition strength, 30
 transmission, 28, 299f, 300f
 transmission electron microscope (TEM),
 4, 51f
 transparency failure, 124–125
 evaluating, 127
 reversing, 131–133
 transparent, 32
 transport coefficient, 93
 transport-of-irradiance equation, 349
 transverse electric (TE), 24–25, 47
 boundary conditions, 49
 polarization, 27–28
 transverse magnetic (TM), 24, 25–26, 49
 Trautman, J.K., 370n
 trichrome stains, 72

trocar, 132f
 tropomodulin, 346, 361
 tropomyosin, 346, 359
 true-color scattering image, 331f
 T-structure, 296f
 tumors, 8
 benign, 8
 malignant, 9
 2D cell culture, 211–212
 2PE. *See* two-photon excitation
 two-photon excitation (2PE), 386
 two-photon luminescence (TPL), 256

U

UBM. *See* ultrasound biomicroscopy
 ultrahigh-resolution OCT, 154–156
 ultrasonography (US), 129, 236
 ultrasound biomicroscopy (UBM), 122
 ultraviolet (UV), 320
 unstained blood smear, 350–351
 unstained tissues, 75
 US. *See* ultrasonography
 uterus, 61f
 UV. *See* ultraviolet

V

van Leeuwenhoek, Antonie, 341
 vascular endothelial growth factor (VEGF),
 130–131
 vector quantity, 91
 VEGF. *See* vascular endothelial growth
 factor
 vertical linkage, 346
 vision, 118–120
 artificial, 135–137
 bilateral loss of, 128f
 testing, 126
 therapeutic tools, 129–137
 vision restoration, 115–137
 visual acuity, 118
 vitrectomy, 133f
 vitrector, 132
 volume plasmon modes, 304
 von Helmholtz, Hermann, 129
 von Middendorff, C., 392

W

wave equation, 18
 wave optics, 116–117
 wave propagation, 175f
 wave vector, 176f
 wavelength-dependent optical absorption,
 301
 WBC. *See* white blood cell
 Webb group, 273
 White, J.G., 371
 white blood cell (WBC), 337
 whole-field plasmon resonance imaging,
 327–332
 Wichmann, J., 373, 374
 wide field geometry, 378
 Wiedenmann, J., 381
 Wildanger, D., 377

Willig, K.I., 377, 382
Wilson, T., 371
World Health Organization, 118

X

X^2 tensor imaging, 273–276
Xenopus, 276
Xenopus laevis, 153, 154, 155f
xylene, 64

Y

Yee's grid, 291

Z

ZEMAX, 117
Zenisek, D., 371